

**Application No.** : 10/665,975  
**Filed:** : September 18, 2003

### **AMENDMENTS TO THE CLAIMS**

1. - 8. (Cancelled)

9. (Withdrawn) An isolated compound that inhibits interaction of Survivin with hepatitis B X-interacting protein (HBXIP), wherein said compound comprises antisense nucleic acids or siRNA that inhibit expression of HBXIP.

10 (Withdrawn) A pharmaceutical composition comprising the compound of Claim 9.

11.-34. (Cancelled)

35. (Withdrawn) The isolated compound of Claim 9, wherein said siRNA comprises about 15 to about 30 nucleotides.

36. (Withdrawn) The isolated compound of Claim 9, wherein said siRNA comprises a modified backbone.

37. (Withdrawn) The isolated compound of Claim 9, wherein said siRNA has greater than 90% identity with a nucleic acid molecule encoding said HBXIP.

38. (Withdrawn) The isolated compound of Claim 9, wherein said antisense nucleic acids have greater than 90% identity with a nucleic acid molecule encoding said HBXIP.

39. (Withdrawn) The isolated compound of Claim 9, wherein said HBXIP is encoded by the nucleic acid sequence shown in SEQ ID NO: 3.

40. (Previously presented) An isolated compound that inhibits anti-apoptotic activity of Survivin, wherein said compound reduces the activity of hepatitis B X-interacting protein (HBXIP) which results in a reduced anti-apoptotic activity of Survivin.

41. (Withdrawn) The isolated compound of Claim 40, wherein said compound comprises an siRNA compound.

42 (Withdrawn) The isolated compound of Claim 41, wherein said siRNA compound has greater than 90% identity with a nucleic acid molecule encoding said HBXIP.

43. (Withdrawn) The isolated compound of Claim 42, wherein said nucleic acid molecule encoding HBXIP comprises a nucleotide sequence of SEQ ID NO: 3.

44. (Withdrawn) The isolated compound of Claim 40, wherein said compound comprises an antisense compound.

**Application No.** : 10/665,975  
**Filed:** : September 18, 2003

45. (Withdrawn) The isolated compound of Claim 44, wherein said antisense compound has greater than 90% identity with a nucleic acid molecule encoding said HBXIP.

46. (Withdrawn) The isolated compound of Claim 45, wherein said nucleic acid molecule encoding HBXIP comprises a nucleotide sequence of SEQ ID NO: 3.

47. (Previously presented) The isolated compound of Claim 40, wherein said compound comprises an antibody.

48. (Previously presented) The isolated compound of Claim 47, wherein said antibody comprises a polyclonal antibody.

49. (Withdrawn) A method of inhibiting survivin, comprising:  
providing the isolated compound of Claim 40; and  
contacting said isolated compound with HBXIP, wherein said contacting results in a reduced anti-apoptotic activity of survivin.

50. (Withdrawn) The method of Claim 49, wherein the isolated compound comprises an siRNA compound.

51. (Withdrawn) The method of Claim 50, wherein said siRNA compound has greater than 90% identity with a nucleic acid molecule encoding said HBXIP.

52. (Withdrawn) The method of Claim 51, wherein said nucleic acid molecule encoding HBXIP comprises a nucleotide sequence of SEQ ID NO: 3.

53. (Withdrawn) The method of Claim 49, wherein said isolated compound comprises an antisense compound.

54. (Withdrawn) The method of Claim 53, wherein said antisense compound has greater than 90% identity with a nucleic acid molecule encoding said HBXIP.

55. (Withdrawn) The method of Claim 54, wherein said nucleic acid molecule encoding HBXIP comprises a nucleotide sequence of SEQ ID NO: 3.

56. (Withdrawn) The method of Claim 49, wherein said isolated compound comprises an antibody.

57. (Withdrawn) The method of Claim 56, wherein said antibody comprises a polyclonal antibody.